Asset Details
Do you wish to reserve the book?
Extracorporeal photopheresis alone or in combination with ruxolitinib for the treatment of chronic graft-versus-host disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Extracorporeal photopheresis alone or in combination with ruxolitinib for the treatment of chronic graft-versus-host disease
Do you wish to request the book?
Extracorporeal photopheresis alone or in combination with ruxolitinib for the treatment of chronic graft-versus-host disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Extracorporeal photopheresis alone or in combination with ruxolitinib for the treatment of chronic graft-versus-host disease
2026
Overview
Chronic graft-versus-host disease (cGvHD) is a major cause of morbidity after allogeneic hematopoietic stem cell transplantation. Ruxolitinib (RUX) is a standard second-line treatment for steroid-refractory or -dependent cGvHD, while extracorporeal photopheresis (ECP), an autologous cell-based immunomodulatory procedure, is also widely used. However, comparative real-world data on combined immunomodulation with the RUX-ECP combination are scarce. We conducted a retrospective single-center analysis of patients with steroid-refractory or -dependent cGvHD receiving RUX-ECP (n=30) or ECP alone (n=21) between 2012 and 2025. The overall response rate was 77% with RUX-ECP and 52% with ECP (p=0.13), with CR rates of 17% and 10% (p=0.69). RUX-ECP was associated with a significantly shorter time to first response (2.6 vs. 12.3 months, p=0.0249). Organ-specific trends favored RUX-ECP in gastrointestinal, ocular and cutaneous cGvHD, whereas both regimens showed limited activity in pulmonary disease. Overall survival, relapse incidence and non-relapse mortality were comparable. At 12 months, complete steroid discontinuation (69% vs. 10%; p=0.005) and relative corticosteroid reduction were significantly greater with RUX-ECP (88% vs. 30%; p=0.0026). Toxicities of RUX-ECP were manageable and consistent with the known RUX profile, and several patients discontinued therapy after stable responses. Thus, combined immunomodulation with RUX-ECP showed high and fast response rates, a favorable safety profile and substantial steroid-sparing, supporting further evaluation in steroid-refractory or -dependent cGvHD patients.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
/ Aged
/ allogeneic hematopoietic stem cell transplantation
/ chronic graft-versus-host disease
/ extracorporeal photopheresis (ECP)
/ Female
/ Graft vs Host Disease - etiology
/ Graft vs Host Disease - mortality
/ Graft vs Host Disease - therapy
/ Hematopoietic Stem Cell Transplantation - adverse effects
/ Humans
/ Leukemia
/ Lymphoma
/ Male
/ Patients
/ Photopheresis - adverse effects
/ Pyrimidines - therapeutic use
/ Steroids
/ Tumors
